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Summary: A polyclonal antibody to human recombinant angiogenin was prepared in rabbits using a
Pam3CysSerGly conjugate. The antibody was then used to develop the first highly sensitive enzyme-labelled
immunometric assay for this vascularisation inducing and tumour associated protein. The assay was suitable
for quantification of angiogenin in body fluids between 2.5 and 0.05 g/l. The mean intra-assay imprecision
was 6.0% and the inter-assay imprecision 7.9%. Angiogenin in human plasma was found to lie in the range
of 0.38 to 0.11 mg/1 with a mean of 0.25 + 0.07 mg/1.
Introduction
Angiogenin is a single chain Afr 14100 protein, first
isolated and characterised from a HT-29 human ad-
enocarcinoma cell line (1). It has been shown to be
an inducer of vascular growth. The protein has 35%
identity with pancreatic ribonuclease (2) and has been
shown to inhibit protein synthesis in vitro (3). Saxena
et al. described angiogenin as a cytotoxic, t-RNA-
specific ribonuclease iii the RNase A superfamily (4).
Angiogenic and ribonucleolytic activities are blocked
by a tight-binding placental ribonuclease inhibitor (5).
Recently, it was shown that angiogenin supports en-
dothelial and fibroblast cell adhesion (6). Shapiro el
al. isolated angiogenin from human plasma (7). Its
mRNA was detected predominantly in the adult liver,
but was also detectable at a low level in other tissues
(8) and cells (9). Detailed information on the presence
of the protein in body fluids and tissues is not avail-
able due to the lack of a sensitive and easily performed
assay.
Here we report the production of a polyclonal anti-
body, which was then used to develop the first sen-
sitive immunometric assay for the determination of
this protein. The method will facilitate an understand-
ing of the role of angiogenin in physiological and
pathophysiological processes.
Materials and Methods
Materials
Nunc Immuno plates II were obtained from Nunc (Roskilde,
Denmark). Horseradish peroxidase1) was obtained from Boeh-
ringer Mannheim (Mannheim, Germany) and 2,2'-azino-bis(3-
ethyl-benzthiazoline-6-sulphonic acid (ABTS) from Sigma (Dei-
senhofen, Germany). Human recombinant angiogenin was
kindly donated by Behringwerke, Marburg. Blood samples were
supplied by Prof. Kleesiek, Herzzentrum Bad Oeynhausen-(Bad
Oeynhausen, Germany). 5-[2,3-bis(palmitoyloxy)propyl]-N-
palmitoyl-cysteinyl-serinyl-glycine-succinimidyl-ester (Pam3
CysSerGlyOSu) and S-[(2J?S)-2,3-bis(palmiloyloxy)-propyl]-N-
palmitoyl-cysteinyl-lysyl-lysyl-lysyl-lysine (Pam3Cys-Ser-Lys4)
were kindly donated by Prof. Jung (Tübingen, Germany).
Methods
Preparation of the S-[2t3,bis(palmitoyloxy)propyl]-N-palmi-
toyl-cysfeinyl-sennyl-glycine/angiogenin (Pam3CysSerGIy/angi-
ogenin) conjugate
Recombinant angiogenin (0.5 mg) was mixed with 5mg
Pam3CysSerGlyOSu in 500 freshly distilled dimethylformam-
ide and incubated under continuous stirring for 15 h at room
temperature. After removal of the dimethylformamide, the
product was dissolved in /-butanol/water (3 + 1, by vol.) and
lyophilised (10).
') Enzyme
Horseradish peroxidase:
donor: hydrogen-peroxide oxidoreductase (EC 1.11.1.7)
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Preparation of the antibodies
PanijCysSerGly/angiogenin conjugate (1 mg) was mixed with
0.5 mg Pam3CysSerLys4 (11), dissolved in phosphate buffered
saline'and injected into rabbits subcutaneously without addi-
tional adjuvants. Further booster immunisations were carried
out in the same manner. The antibodies were purified according
to the method of Harboe & Ingild (12) by salting out and ion
exchange chromatography on DEAE-Sepharose. The IgG-frac-
tion was used in the assay.
Conjugation of horseradish peroxidase to the IgG
The polyclonal IgG was reacted with horseradish peroxidase
by a method described by Tijssen & Kurstak (13).
Sensitivity and precision
The standard curve for angiogenin was used to opti-
mize reaction conditions (fig. 1). The conditions which
gave a good change in colour with the change in
concentration are given above (fig. 2). Intra-(within)-
assay run and inter-(between)-run standard deviations
(SDs) and coefficients of variation (CVs) are sum-
marised in table 1. The working range was calculated
according to the method of Porstmann & Kiesig (14).
Angiogenin can be assayed in the concentration range
between 2.5 and 0.05 μ§/1. Using plasma from several
Two-site immunoenzymometric assay
Microtitre plates were coated with 100 μΐ antibody at 4°C
overnight at a concentration of 2 mg/1 in coating buffer (50
mmol/1 sodium carbonate, pH 9.6). After twice washing with
phosphate buffered saline/Tween (0.2 mol/1 sodium phosphate,
pH 7.4, 0.15. mol/1 NaCl, 0.5 g/1 Tween 20) standards and
samples were diluted in phosphate buffered saline/Tween con-
taining 10 g/1 bovine serum albumin and incubated overnight
at 4 °C or for 2 h at room temperature. Both incubation times
gave similar results. After 4 washes with phosphate buffered
saline/Tween, 100 μΐ of the conjugate solution (IgG/peroxidase-
conjugate 1 : 2000 in phosphate buffered saline/Tween contain-
ing 10 g/1 bovine serum albumin) were placed in each well and
incubated for another 2 h at room temperature. After 6 washes
with phosphate buffered saline/Tween, the substrate reaction
was performed by incubation with ABTS-solution (1 g/1 in 0.1
mol/1 citric acid, adjusted to pH 4.2 with Na2HPO4, 0.5 g/1
Tween 20, 1.3 mmol H2O2). Absorbance was measured using a
Dynatech Microreader MR 4000 (Denkendorf, Germany) at
405 nm. We always used the same antibody for immobilisation
and for peroxidase-labelling.
Recovery experiment
Recovery of angiogenin in plasma. The antigen standards, di-
luted in 0.2 mol/1 phosphate-buffered saline/Tween/bovine se-
rum albumin, were added to the prediluted plasma samples.
This mixture was serially diluted in 8 steps and analysed by
immunoenzymometric assay. Means from those dilutions giving
response of A^nm between 0.2 and 1.5 were selected.
Plasma analysis
Plasma samples of healthy donors were stored at -75 °C until
required. A prediction of 1 :100 was chosen for measurement.
All tests, performed twice on two different days, resulted in
deviations not above the inter-assay coefficients given in table 1.
Results
Production of antibodies
The Pam3CysSerOly/angiogenin conjugate in combi-
nation with Pam3CysSerLys4 as adjuvant was very
effective in the production of antibodies in rabbits.
Remarkably high litres remained constant for over
one year, and more than 0.5 g of antibody could be
gained from one rabbit.
Fig. 1. Standard curve for the sandwich ELISA of angiogenin.
The standard curve was determined under optimised
assay conditions (see Methods). Standard deviations
were calculated from the absorbence values.
0.1
Angiogenin
0.01
Fig. 2. Standard (o) and sample cuwes (· D) for the sandwich
ELISA of angiogenin. All samples were serially diluted
in 0.2 mol/1 phosphate buffered saline/Tween/bovine
serum albumin.
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Tab. 1. Precision of the sandwich ELISA for the determination
of angiogenin in phosphatase-buffered saline/Tween/
bovine serum albumin. In order to ascertain the preci-
sion, profile concentrations were determined from the
absorbance values using prediluted plasma samples at
different concentrations. These concentrations were
used to calculate the standard deviations (SD) and
coefficients of variation (CV).
Concen-
tration
Intra-assay
imprecision (n = 8)
Inter-assay
imprecision (n = 12)
SD CV SD CV
1.700
0.850
0.425
0.213
0.135
0.040
0.023
0.013
7.9
4.7
5.4
6,1
0.145
0.066
0.037
0.014
8.5
7.9
8.6
6.5
donors, it was confirmed that the results always
showed the same proportional response to dilution in
donor plasma and the reference material. Thus, it is
acceptable to record results from the reference curve
(15). The mean analytical recovery tested for concen-
trations between 2.5 and 0.16 μg/l was 99%, which
was very good for this method.
Determination of angiogenin concentrations
in plasma
In order to determine normal ranges for angiogenin
65 plasma samples from healthy donors were ana-
lysed. The measurement was unaffected by repeated
freezing of the sample.
Angiogenin in the plasma was found in the range of
0.38 to 0.11 mg/1 with a mean of 0.25 ± 0.07 mg/1
(fig. 3). There was no significant difference in the
concentrations determined in the plasma of female or
male donors.
Discussion
In this paper, we present the first highly sensitive
assay for angiogenin. The antibodies prepared by the
use of a novel adjuvant were of good affinity and
litre. The sensitivity of the assay was about 300 times
higher than that of a previously reported assay, which
was based on the binding of angiogenin to a placental
ribonuclease inhibitor and measurement of its ribo-
nucleolytic activity (16). The ELISA procedure de-
scribed here is much easier and faster to perform.
Angiogenin has 35% identity with human pancreatic
ribonuclease (2). Since this value is not very high,
cross-reactivity with this ribunuclease is not to be
expected.
Shapiro et al. (7) reported the isolation of angiogenin
from human plasma with a yield of 60—150 μ§/1.
From our studies, there is no doubt that they must
have lost some protein during their purification pro-
cedure. In another paper Bicknell et al. (17) reported
a value of 400 μg/l in human plasma without giving
the assay procedure or number of samples. Our
ELISA procedure represents the first highly reliable
routine determination of angiogenin in plasma sam-
ples and other body fluids.
Angiogenin is a constituent of normal plasma from
healthy donors (7). Its participation as a regulatory
component in vascular growth and blood vessel for-
mation is still unresolved, since vascular growth is
rapid in the developing rat fetus though angiogenin
mRNA levels are low or undetectable (8). Angiogenin
may, however, be involved in such processes in adults
or during wound healing, since the chick chorioallan-
toic assay responds to as little as 35 fmol per egg.
New blood vessels are formed in the rabbit cornea
following application of 3.5 pmol angiogenin (2). An-
giogenin may also be a serum tRNase and it may
hydrolyse tRNA-like molecules outside cells, and per-
haps also inside cells when such molecules gain entry
20
«
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Fig. 3. Distribution of angiogenin in human plasma from healthy donors (n = 65).
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during certain physiological or pathological processes.
A cytotoxic effect was reported for angiogenin when
injected into Xenopus oocytes, and this was related to
its cellular tRNase activity (4). Angiogenin activates
phospholipase C, elicits a rapid incorporation of fatty
acids into cholesterol esters in vascular smooth muscle
cells (18), and depresses the concentration of cAMP
in aortic smooth muscle cells by a mechanism that is
sensitive to pertussis toxin (19).
Since angiogenin is a tumour-derived protein with in
vivo angiogenic activity, first isolated from an estab-
lished human adenocarcinoma cell line (1), it may
also serve as a tumour marker for certain malignant
carcinomas. The ELISA established here will provide
an important tool for assaying the angiogenin con-
centrations of plasma, tissues and tissue fluids, in
order to correlate its concentration with pathological
events.
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